The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline
Open accessAbstract
Abstract Background This document provides clinical recommendations for the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative effort on the part of a panel of expert COPD clinicians and researchers along with a team of methodologists under the guidance of the American Thoracic Society. Methods Comprehensive evidence syntheses were performed on all relevant studies that addressed the clinical questions and critical patient-centered outcomes agreed upon by the panel of experts. The evidence was appraised, rated, and graded, and recommendations were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results After weighing the quality of evidence and balancing the desirable and undesirable effects, the guideline panel made the following recommendations: 1) a strong recommendation for the use of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy in patients with COPD and dyspnea or exercise intolerance; 2) a conditional recommendation for the use of triple therapy with inhaled corticosteroids (ICS)/LABA/LAMA over dual therapy with LABA/LAMA in patients with COPD and dyspnea or exercise intolerance who have experienced one or more exacerbations in the past year; 3) a conditional recommendation for ICS withdrawal for patients with COPD receiving triple therapy (ICS/LABA/LAMA) if the patient has had no exacerbations in the past year; 4) no recommendation for or against ICS as an additive therapy to long-acting bronchodilators in patients with COPD and blood eosinophilia, except for those patients with a history of one or more exacerbations in the past year requiring antibiotics or oral steroids or hospitalization, for whom ICS is conditionally recommended as an additive therapy; 5) a conditional recommendation against the use of maintenance oral corticosteroids in patients with COPD and a history of severe and frequent exacerbations; and 6) a conditional recommendation for opioid-based therapy in patients with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy. Conclusions The task force made recommendations regarding the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are underrepresented in clinical trials is needed, including studies in patients with COPD 80 years of age and older, those with multiple chronic health conditions, and those with a codiagnosis of COPD and asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713901 · Cited by 1,253
Self-citationEffect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease
Niewoehner, D. E., Erbland, M. L., Deupree, R. H., Collins, D., Gross, N. J., Light, R. W., Anderson, P., & Morgan, N. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402502 · Cited by 875
Pascoe, S., Locantore, N., Dransfield, M. T., Barnes, N. C., & Pavord, I. D. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00106-x · Cited by 743
Aaron, S. D., Vandemheen, K. L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., Balter, M., O'Donnell, D., McIvor, A., Sharma, S., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00152 · Cited by 649
Self-citationWithdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
Magnussen, H., Disse, B., Rodriguez-Roisin, R., Kirsten, A., Watz, H., Tetzlaff, K., Towse, L., Finnigan, H., Dahl, R., Decramer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407154 · Cited by 606
Papi, A., Vestbo, J., Fabbri, L., Corradi, M., Prunier, H., Cohuet, G., Guasconi, A., Montagna, I., Vezzoli, S., Petruzzelli, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30206-x · Cited by 603
Wedzicha, J. A., Decramer, M., Ficker, J. H., Niewoehner, D. E., Sandström, T., Taylor, A. F., D'Andrea, P., Arrasate, C., Chen, H., & Banerji, D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70052-3 · Cited by 535
Self-citationAbernethy, A. P., Currow, D. C., Frith, P., Fazekas, B. S., McHugh, A., & Bui, C. (2003) · BMJ · doi:10.1136/bmj.327.7414.523 · Cited by 521
Vestbo, J., Papi, A., Corradi, M., Blazhko, V., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., & Singh, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30188-5 · Cited by 425
Siddiqui, S. H., Guasconi, A., Vestbo, J., Jones, P., Agusti, A., Paggiaro, P., Wedzicha, J. A., & Singh, D. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0235le · Cited by 415
Self-citationDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Bateman, E. D., Ferguson, G. T., Barnes, N., Gallagher, N., Green, Y., Henley, M., & Banerji, D. (2013) · European Respiratory Journal · doi:10.1183/09031936.00200212 · Cited by 388
Ferguson, G. T., Rabe, K. F., Martinez, F. J., Fabbri, L. M., Wang, C., Ichinose, M., Bourne, E., Ballal, S., Darken, P., DeAngelis, K., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30327-8 · Cited by 379
Self-citationBlood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
Pavord, I. D., Lettis, S., Locantore, N., Pascoe, S., Jones, P. W., Wedzicha, J. A., & Barnes, N. C. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207021 · Cited by 327
Self-citationTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., Fležar, M., Hébert, J., McGarvey, L., Pizzichini, E., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00136014 · Cited by 315
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
Donohue, J. F., Maleki-Yazdi, M. R., Kilbride, S., Mehta, R., Kalberg, C., & Church, A. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.06.001 · Cited by 259
Chapman, K. R., Hurst, J. R., Frent, S.-M., Larbig, M., Fogel, R., Guerin, T., Banerji, D., Patalano, F., Goyal, P., Pfister, P., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201803-0405oc · Cited by 251
Self-citationWoodcock, A. A., Gross, E. R., Gellert, A., Shah, S., Johnson, M., & Geddes, D. M. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112313052703 · Cited by 242
Pascoe, S., Barnes, N., Brusselle, G., Compton, C., Criner, G. J., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Hartley, B., Lange, P., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30190-0 · Cited by 241
Self-citationDecramer, M., Anzueto, A., Kerwin, E., Kaelin, T., Richard, N., Crater, G., Tabberer, M., Harris, S., & Church, A. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70065-7 · Cited by 235
Calverley, P. M. A., Anzueto, A. R., Carter, K., Grönke, L., Hallmann, C., Jenkins, C., Wedzicha, J., & Rabe, K. F. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30102-4 · Cited by 189
Self-citationSingh, D., Jones, P. W., Bateman, E. D., Korn, S., Serra, C., Molins, E., Caracta, C., Gil, E. G., & Leselbaum, A. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-178 · Cited by 176
Effects of Long-term Treatment With Corticosteroids in COPD
Renkema, T. E., Schouten, J. P., Koëter, G. H., & Postma, D. S. (1996) · Chest · doi:10.1378/chest.109.5.1156 · Cited by 176
Tiotropium + olodaterol shows clinically meaningful improvements in quality of life
Singh, D., Ferguson, G. T., Bolitschek, J., Grönke, L., Hallmann, C., Bennett, N., Abrahams, R., Schmidt, O., & Bjermer, L. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.08.002 · Cited by 175
Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study
Vogelmeier, C., Kardos, P., Harari, S., Gans, S. J. M., Stenglein, S., & Thirlwell, J. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.07.020 · Cited by 172
Light, R. W., Muro, J. R., Sato, R. I., Stansbury, D. W., Fischer, C. E., & Brown, S. E. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/139.1.126 · Cited by 166
Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD
Celli, B. R., Crater, G., Kilbride, S., Mehta, R. S., Tabberer, M. M., Kalberg, C. J., & Church, A. (2014) · CHEST Journal · doi:10.1378/chest.13-1579 · Cited by 155
Mahler, D. A., Kerwin, E., Ayers, T. S., FowlerTaylor, A., Maitra, S., Thach, C. T., Lloyd, M. L., Patalano, F., & Banerji, D. D. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-1048oc · Cited by 126
Maleki-Yazdi, M. R., Kaelin, T., Richard, N., Zvarich, M. T., & Church, A. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.10.002 · Cited by 126
Poole, P., Veale, A. G., & BLACK, P. N. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9711061 · Cited by 122
Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease.
Young, I. H., Daviskas, E., & Keena, V. A. (1989) · Thorax · doi:10.1136/thx.44.5.387 · Cited by 120
Dihydrocodeine for breathlessness in "pink puffers".
Johnson, M. A., Woodcock, A. A., & Geddes, D. M. (1983) · BMJ · doi:10.1136/bmj.286.6366.675 · Cited by 117
Mahler, D. A., D'Urzo, A., Bateman, E. D., Özkan, S. A., White, T., Peckitt, C., Lassen, C., Kramer, B., & on behalf of the INTRUST-1 and INTRUST-2 study investigators (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201140 · Cited by 105
Martínez, F. J., Rabe, K. F., Ferguson, G. T., Fabbri, L. M., Rennard, S. I., Feldman, G., Sethi, S., Spangenthal, S., Gottschlich, G. M., Rodriguez‐Roisin, R., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.11.028 · Cited by 105
Jensen, D., Alsuhail, A., Viola, R., Dudgeon, D. J., Webb, K. A., & O’Donnell, D. E. (2011) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.05.007 · Cited by 99
Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome
Eiser, N. M., Denman, W. T., West, C., & Luce, P. J. (1991) · European Respiratory Journal · doi:10.1183/09031936.93.04080926 · Cited by 84
Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine
Noseda, A., Carpiaux, J. P., Markstein, C., Meyvaert, A., & Maertelaer, V. D. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10051079 · Cited by 80
Maltais, F., Singh, S., Donald, A., Crater, G., Church, A., Goh, A. H., & Riley, J. (2014) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465814559209 · Cited by 73
Weir, D. C., & Burge, P. S. (1993) · Thorax · doi:10.1136/thx.48.4.309 · Cited by 70
Hanania, N. A., Tashkin, D. P., Kerwin, E., Donohue, J. F., Denenberg, M., O’Donnell, D. E., Quinn, D., Siddiqui, S. S., Orevillo, C., Maes, A. L., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.03.015 · Cited by 70
Li, S., Alexander, P. E., Reljic, T., Cuker, A. C., Nieuwlaat, R., Wiercioch, W., Guyatt, G. H., Schünemann, H. J., & Djulbegović, B. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.09.007 · Cited by 69
Self-citationTashkin, D. P., Donohue, J. F., Mahler, D. A., Huang, H., Goodwin, E., Schaefer, K., Hanrahan, J. P., & Andrews, W. T. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.12.014 · Cited by 68
Beauford, W., Saylor, T. T., Stansbury, D. W., Avalos, K., & Light, R. W. (1993) · CHEST Journal · doi:10.1378/chest.104.1.175 · Cited by 64
Light, R. W., Stansbury, D. W., & Webster, J. S. (1996) · CHEST Journal · doi:10.1378/chest.109.4.975 · Cited by 61
LEUNG, R., Hill, P. A., & BURDON, J. G. W. (1996) · Thorax · doi:10.1136/thx.51.6.596 · Cited by 60
Jankelson, D., Hosseini, K., Mather, L. E., Seale, J. P., & Young, I. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10102270 · Cited by 46
Shohrati, M., Ghanei, M., Harandi, A. A., Foroghi, S., & Harandi, A. A. (2012) · Pulmonary Medicine · doi:10.1155/2012/610921 · Cited by 30
Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease
Davies, L. (1999) · QJM · doi:10.1093/qjmed/92.7.395 · Cited by 28
Cited by
MacLeod, M., Papi, A., Contoli, M., Beghé, B., Celli, B. R., Wedzicha, J. A., & Fabbri, L. M. (2021) · Respirology · doi:10.1111/resp.14041 · Cited by 359
Self-citationCOPD and multimorbidity: Recognising and addressing a syndemic occurrence
Fabbri, L. M., Celli, B. R., Agustí, A., Criner, G. J., Dransfield, M. T., Divo, M., Krishnan, J. K., Lahousse, L., Montes de Oca, M., Salvi, S. S., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00261-8 · Cited by 274
Self-citation
Metadata
- Authors
- Nici, L., Mammen, M. J., Charbek, E., Alexander, P. E., Au, D. H., Boyd, C. M., Criner, G. J., Donaldson, G. C., Dreher, M., Fan, V. S., Gershon, A. S., Han, M. K., Krishnan, J. A., Martinez, F. J., Meek, P. M., Morgan, M., Polkey, M. I., Puhan, M. A., Sadatsafavi, M., Sin, D. D., Washko, G. R., Wedzicha, J. A., & Aaron, S. D.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-01
- Volume
- 201
- Issue
- 9
- Pages
- e56-e69
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W3016201212
- Cited by
- 316
- References
- 49
- FWCI
- 25.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.